Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Plasmapheresis — When to Use It, How Often, and What Clinical Problems Truly Benefit
Hossam Qassem/LinkedIn
Nov 26, 2025, 03:00

Plasmapheresis — When to Use It, How Often, and What Clinical Problems Truly Benefit

Hossam Qassem, ICU Clinical pharmacist at Mabaret AlAsafra Group for Medical Services, shared a post on LinkedIn:

“Day 70

Plasmapheresis — When to Use It, How Often, and What Clinical Problems Truly Benefit

Key Clinical Pearls

1. What Plasmapheresis Does — Core Mechanism

Therapeutic plasma exchange (TPE) removes pathologic circulating factors:
✔ Autoantibodies
✔ Immune complexes
✔ Paraproteins
✔ Toxins bound to plasma proteins
Replaced with: albumin, FFP, or a mix depending on indication.

2. Strong Indications (Category I — ASFA)

Plasmapheresis is first-line in:

TTP (thrombotic thrombocytopenic purpura) → life-saving

Guillain–Barré syndrome (GBS)

Myasthenia gravis crisis

ANCA-associated rapidly progressive glomerulonephritis (selected severe cases)

Goodpasture syndrome (anti-GBM disease)

Hyperviscosity syndrome (Waldenström macroglobulinemia)

Hematopoietic stem cell transplant–associated TMA

Severe autoimmune hemolytic anemia refractory to steroids

Certain drug toxicities (e.g., Amanita phalloides, TCA toxicity—rare but documented if highly protein-bound)

3. Important Secondary Indications (Category II–III)

Used as adjunct therapy in:

CIDP

Multiple sclerosis fulminant relapse

Neuromyelitis optica spectrum disorder (NMOSD)

Catastrophic antiphospholipid syndrome

Autoimmune encephalitis (e.g., anti-NMDA)

Antibody-mediated rejection post-transplant

Cryoglobulinemia with end-organ involvement

Fulminant Wilson disease

Rhabdomyolysis with myoglobin removal (select cases)

4. Typical Frequency and Medicine, Health, Hemostasis, Hemostasis Today, HematologyCourse (Practical ICU Schedule)

Most autoimmune/neurologic conditions:

1 session every day or every other day
Total: 5–7 sessions
(Each exchange removes ~60–70% of plasma antibodies per session.)

TTP:

Daily exchanges, sometimes twice daily if severe

Continue until platelet count normal + hemolysis markers stabilize
(Usually 5–10 days)

Myasthenia crisis / GBS:
One session every other day
Total: 4–6 sessions

Hyperviscosity syndrome:
Single session usually effective
Repeat if symptoms recur

Goodpasture / ANCA vasculitis:
Daily or every-other-day sessions
Total: 7–14 sessions depending on autoantibody titers

Antibody-mediated transplant rejection:
every 1–2 days
Combined with IVIG ± rituximab

5. What to Monitor During Therapy

✔ Ionized calcium during citrate anticoagulation
✔ Coagulation profile (especially if using albumin—no clotting factors)
✔ Hemodynamic stability
✔ Electrolytes (Mg, Ca)
✔ Fibrinogen levels — replenish if <150 mg/dL
✔ Antibody titers to guide duration in anti-GBM or AMR

6. Clinical Pearls — Practical Pharmacist/ICU Notes

Using FFP is mandatory in TTP (replaces ADAMTS13).

Avoid placing central lines in coagulopathic patients without correction.

TPE removes many medications — adjust dosing for:
rituximab, IVIG, tacrolimus, mycophenolate, phenytoin, vancomycin, and some monoclonal antibodies.

Always dose immunosuppressives after the session, not before.

Consider post-exchange IVIG in autoimmune disorders to restore immune balance.”

Plasmapheresis — When to Use It, How Often, and What Clinical Problems Truly Benefit

Stay informed with Hemostasis Today.

Albumin Autoimmune Diseases FFP Guillain–Barré syndrome (GBS) Health Hematology Hemostasis Hemostasis Today Medicine Myasthenia gravis crisis Neuromyelitis optica spectrum disorder (NMOSD) Plasmapheresis TTP (thrombotic thrombocytopenic purpura)
NewsFeed